NUWE NUWELLIS INC

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Live video webcast on Thursday, August 21st at 2:40 PM ET

MINNEAPOLIS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it will present at the being held virtually August 19-21, 2025.

Details for the presentation are as follows:

Date/Time: Thursday, August 21, 2025 at 2:40 PM ET

Presenter: Registration Link:

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X, formerly known as Twitter.

For further information, please contact:

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

Media Contact:

Leah McMullen

Director of Communications



EN
15/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-B...

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The new circuit is designed for single-day outpatient sessions and complements the company’s existing 72-hour option that is commonly used for multi-day therapy or inpatient care. Together, these options help hospitals match supply to setting while maintaining a consistent therapy ...

 PRESS RELEASE

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Len...

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). Advancing a broader fluid management platform: This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and practical ...

 PRESS RELEASE

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech L...

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal MINNEAPOLIS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on improving patient outcomes through advanced fluid management, today announced it has signed a non-binding letter of i...

 PRESS RELEASE

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect We...

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Live video webcast on Thursday, August 21st at 2:40 PM ET MINNEAPOLIS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Thursday, August 21, 2025 at 2:40 PM ET Presenter: Registration Link: About Webull Financial Webull Finan...

 PRESS RELEASE

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Busin...

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic realignment during the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch